Effects of l-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia

Hemodialysis International

Volumn 14, Issue 4, 2010, Pages 498-504

  Shakeri, Azam ^a   Tabibi, Hadi ^a   Hedayati, Mehdi ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hemodialysis; Inflammation; l carnitine; Lp (a); Oxidative stress

Indexed keywords

C REACTIVE PROTEIN; CALCITRIOL; CALCIUM CARBONATE; CARNITINE; CYTOKINE; FOLIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPROTEIN; LIPOPROTEIN A; OXIDIZED LOW DENSITY LIPOPROTEIN; PYRIDOXINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE MARKER; DRUG EFFECT; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERLIPOPROTEINEMIA; INFLAMMATION; KIDNEY FAILURE; LIPOPROTEIN BLOOD LEVEL; MALE; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARNITINE; CYTOKINES; DIETARY SUPPLEMENTS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIAS; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPROTEIN(A); LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77958600062     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2010.00476.x     Document Type: Article

References (33)

1. Singh SK, Brenner BM. Dialysis in the treatment of renal failure. Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principle of Internal Medicine. 5th ed. New York: McGraw-Hill; 2001:1562-1566.
2. Jungers P, Khoa TN, Massy ZA, et al. Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patient: A multicentric study in the Ile de France district. Nephrol Dial Transplant. 1999; 14:898-902.
3. Stenvinkel P. Inflammation in end-stage renal failure: Could it be treated? Nephrol Dial Transplant. 2002; 17 (Suppl 8):33-38.
4. Stenvinkel P, Yeun JY. Role of inflammation in malnutrition and atherosclerosis in chronic renal failure. Kopple JD, Massry SG, eds. Kopple and Massry's Nutritional Management of Renal Disease. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2004:199-212.
5. Horl WH. Oxidant stress. Kopple JD, Massry SG, eds. Kopple and Massry's Nutritional Management of Renal Disease. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2004:99-110.
6. Jacobs P, Glorieux G, Vanholder R. Interleukin/cytokine profiles in haemodialysis and in continuous peritoneal dialysis. Nephrol Dial Transplant. 2004; 19 (Suppl 5):v41-v45.
7. Wanner C. Lipid metabolism in renal disease and renal failure. Kopple JD, Massry SG, eds. Nutrition Management of Renal Disease. 1st ed. New York: Williams & Wilkins; 1997:35-62.
8. Wanner C. Altered lipid metabolism and serum lipids in renal disease and renal failure. Kopple JD, Massary SG, eds. Kopple and Massary's Nutritional Management of Renal Disease. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2004:42-55.
9. Sirtori CR, Calabresi L, Ferrara S, et al. l-carnitine reduces plasma lipoprotein (a) levels in patients with hyper Lp(a). Nutr Metab Cardiovasc Dis. 2000; 10:247-251.
10. Derosa G, Cicero AFG, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. The effect of l-carnitine on plasma lipoprotein (a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther. 2003; 25:1429-1439.
11. Savica V, Santoro D, Mazzaglia G, et al. l-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. J Ren Nutr. 2005; 15:225-230.
12. Duranay M, Akay H, Yilmaz FM, Senes M, Tekeli N, Yucel D. Effects of l-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. Nephrol Dial Transplant. 2006; 21:3211-3214.
13. Daugirdas JT, Stone JCV. Physiologic principles and urea kinetic modeling. Daugirdas JT, Blake PG, Ing TS, eds. Handbook of Dialysis. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001:15-45.
14. Evans A. Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis. 2003; 41 (Suppl 4):S13-S26.
15. Alberty R, Albertyova D. Biological variation of free and total carnitine in serum of healthy subjects. Clin Chem. 1997; 43:2441-2443.
16. Guarnieri G, Biolo G, Vinci P, Massolino B, Barazzoni R. Advances in carnitine in chronic uremia. J Ren Nutr. 2007; 17:23-29.
17. Elisaf M, Bairaktari E, Katopodis K, et al. Effect of l-carnitine supplementation on lipid parameters in hemodialysis patients. Am J Nephrol. 1998; 18:416-421.
18. Hull A. Renal Nutrition. 5th ed. Ashland: Nutrition Dimension; 2004, p. 190.
19. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004; 279:48487-48490.
20. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol. 2003; 41:37S-42S.
21. Clearfield MB. C-reactive proteA new risk assessment tool for cardiovascular disease. JAOA. 2005; 105:409-416.
22. Winter BK, Fiskum G, Gallo LL. Effects of l-carnitine on serum triglyceride and cytokine levels in rat models of cachexia and septic shock. Br J Cancer. 1995; 72:1173-1179.
23. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. High serum lipoprotein (a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol. 1992; 38:271-276.
24. Dahlen GH, Stenlund H. Lp (a) lipoprotein is a major risk factor for cardiovascular disease: Pathogenic mechanisms and clinical significance. Clin Genet. 1997; 52:272-280.
25. Heimburger O, Stenvinkel P, Berglund L, Tranoeus A, Lindholm B. Increased plasma lipoprotein (a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Nephron. 1996; 72:135-144.
26. Siamopoulos KC, Elisaf MS, Bairaktari HT, Pappas MB, Sferopoulos GD, Nikolakakis NG. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis (abstract). Perit Dial Int. 1995; 15:342-347.
27. Garcia-Lopez E, Carrero JJ, Suliman ME, Lindholm B, Stenvinkel P. Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Perit Dial Int. 2007; 27 (Suppl 2):S205-S209.
28. Superko HR. Did grandma give you heart disease? The new battle against coronary artery disease. Am J Cardiol. 1998; 82:34Q-46Q.
29. Spinler SA, Cziraky MJ. Lipoprotein (a): Physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy. Ann Pharmacother. 1994; 28:343-351.
30. Djurovic S, Berg K. Epidemiology of Lp(a) lipoproteIts role in atherosclerotic/thrombotic disease. Clin Genet. 1997; 52:281-292.
31. Tetta C, Biasiol S, Schiavon R, et al. An overview of haemodialysis and oxidant stress. Blood Purif. 1999; 17:118-126.
32. Canaud B, Cristol JP, Morena M, Leray-Moragues H, Bosc JY, Vaussenat F. Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif. 1999; 17:99-106.
33. Galli F, Ronco C. Oxidant stress in hemodialysis. Nephron. 2000; 84:1-5.